![](https://www.businessmarketinsights.com/assets/img/reports-icon.png)
아시아 태평양 심혈관 대사 질환 시장 예측(2028년) – 유형별(심혈관 질환(CVD), 제2형 당뇨병, 고혈압 및 비만), 치료(ACE 억제제, 이뇨제, 글루코파지 등), 복용량( 정제, 주사제), 투여 경로(경구 및 정맥 주사), 최종 사용자(병원, 진료소, 홈케어 환경), 유통 경로(병원 약국, 소매 약국, 온라인 약국)
시장 소개
심장대사질환은 다음과 같은 일련의 이상과 증상이 특징입니다. 개인의 심혈관 질환 발병 위험. 고혈압, 비만, 인슐린 저항성, 이상지질혈증, 나쁜 콜레스테롤 수치(LDL), 포도당 내성 등이 증상 중 일부입니다. 심장대사증후군을 앓고 있는 사람은 제2형 당뇨병, 뇌졸중, 관상동맥질환(CAD), 심혈관질환(CVD) 등 생명을 위협하는 여러 가지 질병에 걸리기 쉽습니다.
또한, 심장대사 질환의 유병률 증가로 인해 예측 기간 동안 시장 성장이 강화될 것으로 예상됩니다. 그러나 저소득 및 중간 소득 국가(LMIC)의 심혈관 질환 진단 부족으로 인해 아시아 태평양 심혈관 대사 질환 시장의 성장이 제한되고 있습니다.
공급망 중단과 이에 대한 막대한 수요 코로나19 치료를 위한 효율적인 치료법으로 인해 아시아 태평양 지역의 의료 연구 산업이 중요한 상황에 놓였습니다. 이 전염병의 확산을 통제하기 위해 금지 조치가 취해졌습니다. 코로나19 팬데믹(세계적 대유행)은 아시아 태평양 지역 경제에 광범위하게 영향을 미쳤습니다. 인도(31,769,132), 일본(956,407), 중국(93,289), 한국(203,926) 등의 국가가 팬데믹으로 인해 부정적인 영향을 받았습니다. 마이너스 인플레이션, GDP 증가, 지역 실업률 급증 등 사회경제적 측면이 심각한 영향을 받았습니다. 최근 일본에서는 고혈압과 비만을 동시에 앓고 있는 환자가 증가하고 있다. 이들 환자는 코로나19 중증질환 고위험군에 속하므로 세심한 관찰과 집중적인 치료가 필요하다. 고혈압과 비교하여 비만의 정의는 연구/국가마다 일정하지 않으므로 고려가 필요합니다. 그러나 코로나19에 대한 CCB의 치료 메커니즘은 여전히 추가 조사와 무작위 대조 임상 시험을 기다리고 있다는 점에 유의해야 합니다.
시장 개요 및 역학
아시아 태평양 심장대사 질환 시장은 2021년 210억 9130만 달러에서 2028년 289억 5320만 달러에 이를 것으로 예상됩니다. 2021년부터 2028년까지 연평균 성장률(CAGR) 4.6%로 성장할 것으로 예상됩니다. 심혈관대사 질환(CMD)은 전 세계적으로 사망의 주요 원인 중 하나입니다. 이러한 질병은 주로 건강에 해로운 생활 방식, 신체 활동 부족, 흡연 및 건강에 해로운 식습관으로 인해 발생합니다. CMD에는 심혈관 질환(CVD), 당뇨병, 만성 신부전이 포함됩니다. 대부분의 심혈관 질환은 흡연, 건강에 해로운 식습관 선택, 비만, 신체 활동 부족 및 음주와 같은 행동 위험 요인을 해결함으로써 예방할 수 있습니다. 당뇨병은 기능적 치료법이 없는 생명을 위협하는 만성질환 중 하나이다. 이는 다양한 합병증을 일으키고 조기 사망의 전반적인 위험을 증가시킵니다. 심장 마비, 뇌졸중, 신부전, 다리 절단, 시력 상실 및 신경 손상은 당뇨병과 관련된 주요 합병증입니다. 흡연 증가, 운동부족, 음주, 건강에 해로운 식습관 등으로 인해 CMD를 하나 이상 갖고 있는 사람이 늘어나고 있습니다. 비만 유병률이 증가함에 따라 CMD로 고통받는 환자 기반도 늘어나고 있습니다. CMD 유병률이 급격히 증가함에 따라 적절한 심장 대사 질환 치료에 대한 필요성이 급증하여 아시아 태평양 심장 대사 질환 시장이 엄청나게 성장했습니다.
< u>주요 시장 부문
유형 면에서 심혈관 질환 부문은 2020년 아시아 태평양 심장대사 질환 시장에서 가장 큰 점유율을 차지했습니다. 치료 측면에서는 ACE 억제제 부문이 2020년 아시아태평양 심혈관대사질환 시장에서 가장 큰 점유율을 차지했고, 복용량 측면에서는 정제 부문이 2020년 아시아태평양 심혈관대사질환 시장에서 가장 큰 점유율을 차지했다. 투여 경로 측면에서 보면 경구 부문이 2020년 아시아 태평양 심혈관 대사 질환 시장에서 가장 큰 점유율을 차지했습니다. 최종 사용자 측면에서 보면 병원 부문이 2020년 아시아 태평양 심혈관 대사 질환 시장에서 가장 큰 점유율을 차지했습니다. 유통 채널에서는 병원 약국 부문 이 2020년에 가장 큰 시장 점유율을 차지했습니다.
주요 출처 및 상장 회사 u>
아시아 태평양 지역의 심장대사 질환 시장에 대한 이 보고서를 준비하기 위해 참조된 몇 가지 주요 1차 및 2차 소스는 회사 웹사이트, 연례 보고서, 재무 보고서입니다. , 국가 정부 문서, 통계 데이터베이스 등이 있습니다. 보고서에 나열된 주요 회사로는 Eli Lilly and Company., Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, AstraZeneca, Cardax Inc. 및 Kowa Company, Ltd.
보고서 구매 이유
- 아시아 태평양 심장대사 질환 시장 환경을 이해하고 강력한 수익을 보장할 수 있는 시장 부문을 식별
- 끊임없이 변화하는 시장 환경을 이해하고 이를 유지하기 위해 경쟁 우위
- 가장 유망한 판매 가능성이 있는 부문을 식별하여 아시아 태평양 심혈관 질환 시장에서 인수합병 및 파트너십 거래를 효율적으로 계획합니다.
- 다양한 부문의 시장 성과에 대한 통찰력 있고 포괄적인 분석을 통해 현명한 비즈니스 결정을 내리기 위해
- 아시아 태평양 지역의 시장 수익 예측을 얻기 위해 2021년부터 2028년까지 다양한 세그먼트를 기반으로 한 심장 대사 질환 시장
아시아 태평양 심장 대사 질환 시장 세분화
기준 유형
- 심혈관 질환(CVD)
- 제2형 당뇨병
- 고혈압
- 비만
치료에 따른
- ACE 억제제
- 이뇨제
- 글루코파지
- 기타
복용량 기준
- 정제
- 주사
투여 경로별
- 경구
- 정맥 주사
최종 사용자에 의한
- 병원
- 클리닉
- 홈케어 설정  ;
유통 채널별
- 병원 약국 span>
- 소매 약국
- 온라인 약국
국가별
- 아시아 태평양
- 중국
- 일본
- 인도
- 대한민국
- 호주
- 나머지 아시아 태평양
언급된 회사 Strong>
- 엘리 릴리 앤 컴퍼니.
- 바이엘 AG
- 노바티스 AG   ;
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Kowa Company, Ltd.
- Cardax, Inc.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.7 Asia Pacific Cardiometabolic Diseases market – By Country
2. Asia Pacific Cardiometabolic Diseases Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Cardiometabolic Diseases Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinions
5. Asia Pacific Cardiometabolic Diseases Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cardiometabolic Diseases
5.1.2 Innovation in Cardiometabolic Diseases Therapeutics
5.2 Market Restraints
5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs)
5.3 Market Opportunities
5.3.1 Technological Advancements in CMD Diagnosis
5.4 Future Trends
5.4.1 Personalized Treatment for CMDs
5.5 Impact Analysis
6. Asia Pacific Cardiometabolic Diseases Market – Regional Analysis
6.1 Asia Pacific Cardiometabolic Diseases Market Revenue Forecast And Analysis
7. Asia Pacific Cardiometabolic Diseases Market Analysis – By Type
7.1 Overview
7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
7.3 Cardiovascular Disease (CVD)
7.3.1 Overview
7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Hypertension
7.4.1 Overview
7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Type 2 Diabetes
7.5.1 Overview
7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Obesity
7.6.1 Overview
7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8. Asia Pacific Cardiometabolic Diseases Market Analysis – By Treatment
8.1 Overview
8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
8.3 ACE inhibitors
8.3.1 Overview
8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diuretics
8.4.1 Overview
8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Glucophage
8.5.1 Overview
8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Others
8.6.1 Overview
8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9. Asia Pacific Cardiometabolic Diseases Market Analysis – By Dosage
9.1 Overview
9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
9.3 Tablet
9.3.1 Overview
9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Injection
9.4.1 Overview
9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
10. Asia Pacific Cardiometabolic Diseases Market Analysis – By Route of Administration
10.1 Overview
10.2 Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Intravenous
10.4.1 Overview
10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn)
11. Asia Pacific Cardiometabolic Diseases Market Analysis – By End User
11.1 Overview
11.2 Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
11.3 Clinic
11.3.1 Overview
11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Hospital
11.4.1 Overview
11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Homecare Settings
11.5.1 Overview
11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn)
12. Asia Pacific Cardiometabolic Diseases Market Analysis – By Distribution Channel
12.1 Overview
12.2 Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
12.3 Hospital Pharmacy
12.3.1 Overview
12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.4 Retail Pharmacy
12.4.1 Overview
12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.5 Online Pharmacy
12.5.1 Overview
12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
13. Asia Pacific Cardiometabolic Diseases Market – Geographic Analysis
13.1 Asia Pacific: Cardiometabolic Diseases Market
13.1.1 Overview
13.1.2 Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.3 Asia Pacific: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.4 Asia Pacific: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.5 Asia Pacific: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.6 Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.7 Asia Pacific: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.8 Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.9 Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
13.1.9.1 China: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.9.1.1 China: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.10 China: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.11 China: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.12 China: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.13 China: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.14 China: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.15 China: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.15.1 Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.15.1.1 Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.16 Japan: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.17 Japan: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.18 Japan: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.19 Japan: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.20 Japan: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.21 Japan: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.21.1 India: Cardiometabolic Diseases Market - Revenue and Forecasts to 2028 (USD Million)
13.1.21.1.1 India: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.22 India: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.23 India: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.24 India: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.25 India: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.26 India: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.27 India: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.27.1 South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.27.1.1 South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.28 South Korea: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.29 South Korea: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.30 South Korea: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.31 South Korea: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.32 South Korea: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.33 South Korea: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.33.1 Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.33.1.1 Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.34 Australia: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.35 Australia: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.36 Australia: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.37 Australia: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.38 Australia: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.39 Australia: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.39.1 Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.39.1.1 Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.40 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.41 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.42 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.43 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.44 Rest of Asia Pacific: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.45 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
14. Impact of COVID-19 Pandemic on Asia Pacific Cardiometabolic Diseases Market
14.1 Asia Pacific: Impact Assessment of COVID-19 Pandemic
15. Asia Pacific Cardiometabolic Diseases Market – Industry Landscape
15.1 Overview
15.2 Growth Strategies in the Cardiometabolic Diseases Market (%)
15.3 Organic Developments
15.3.1 Overview
15.4 Inorganic Developments
15.4.1 Overview
16. Company Profiles
16.1 Eli Lilly and Company.
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
16.2 Bayer AG
16.2.1 Key Facts
16.2.2 Business Description
16.2.3 Products and Services
16.2.4 Financial Overview
16.2.5 SWOT Analysis
16.2.6 Key Developments
16.3 Novartis AG
16.3.1 Key Facts
16.3.2 Business Description
16.3.3 Products and Services
16.3.4 Financial Overview
16.3.5 SWOT Analysis
16.3.6 Key Developments
16.4 Boehringer Ingelheim International GmbH
16.4.1 Key Facts
16.4.2 Business Description
16.4.3 Products and Services
16.4.4 Financial Overview
16.4.5 SWOT Analysis
16.4.6 Key Developments
16.5 Novo Nordisk A/S
16.5.1 Key Facts
16.5.2 Business Description
16.5.3 Products and Services
16.5.4 Financial Overview
16.5.5 SWOT Analysis
16.5.6 Key Developments
16.6 AstraZeneca
16.6.1 Key Facts
16.6.2 Business Description
16.6.3 Products and Services
16.6.4 Financial Overview
16.6.5 SWOT Analysis
16.6.6 Key Developments
16.7 Cardax, Inc.
16.7.1 Key Facts
16.7.2 Business Description
16.7.3 Products and Services
16.7.4 Financial Overview
16.7.5 SWOT Analysis
16.7.6 Key Developments
16.8 Kowa Company, Ltd.
16.8.1 Key Facts
16.8.2 Business Description
16.8.3 Products and Services
16.8.4 Financial Overview
16.8.5 SWOT Analysis
16.8.6 Key Developments
17. Appendix
17.1 About The Insight Partners
17.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 2. Asia Pacific Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 3. Asia Pacific Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 4. Asia Pacific Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 5. Asia Pacific Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 6. Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 7. China Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 8. China Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 9. China Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 10. China Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 11. China Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 12. China Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 13. Japan Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 14. Japan Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 15. Japan Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 16. Japan Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 17. Japan Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 18. Japan Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 19. India Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 20. India Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 21. India Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 22. India Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 23. India Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 24. India Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 25. South Korea Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 26. South Korea Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 27. South Korea Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 28. South Korea Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 29. South Korea Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 30. South Korea Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 31. Australia Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 32. Australia Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 33. Australia Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 34. Australia Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 35. Australia Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 36. Australia Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 37. Rest of Asia Pacific Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 38. Rest of Asia Pacific Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 39. Rest of Asia Pacific Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 40. Rest of Asia Pacific Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 41. Rest of Asia Pacific Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 42. Rest of Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 43. Organic Developments in the Cardiometabolic Diseases Market
Table 44. Inorganic Developments in the Cardiometabolic Diseases Market
Table 45. Glossary of Terms, Asia Pacific Cardiometabolic Diseases Market
LIST OF FIGURES
Figure 1. Asia Pacific Cardiometabolic Diseases Market Segmentation
Figure 2. Asia Pacific Cardiometabolic Diseases Market Overview
Figure 3. Cardiovascular Disease (CVD) Segment Held Largest Share of Type of Asia Pacific Cardiometabolic Diseases Market
Figure 4. Asia Pacific Cardiometabolic Diseases Market – Leading Country Markets (US$ Million)
Figure 5. Asia Pacific Cardiometabolic Diseases Market, Industry Landscape
Figure 6. Asia Pacific PEST Analysis
Figure 7. Asia Pacific Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints
Figure 8. Asia Pacific Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028
Figure 9. Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
Figure 10. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 11. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
Figure 15. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 18. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 19. Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
Figure 20. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 21. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 22. Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
Figure 23. Oral Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 24. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 25. Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
Figure 26. Clinic Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. Hospital Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 28. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
Figure 30. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 31. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 32. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 33. Asia Pacific: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million)
Figure 34. Asia Pacific Cardiometabolic Diseases Market Revenue and Forecast to 2028 (USD Million)
Figure 35. Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
Figure 36. China Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 37. Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 38. India: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 39. South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 40. Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 41. Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 42. Impact of COVID-19 Pandemic on Asia Pacific Cardiometabolic Diseases Market
Figure 43. Growth Strategies in the Cardiometabolic Diseases Market (%)
- Eli Lilly and Company.
- Bayer AG
- Novartis AG
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Kowa Company, Ltd.
- Cardax, Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific cardiometabolic diseases market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.